Abstract
dc:description.abstractPregnancy-associated osteoporosis (PAO) is a rare condition affecting women during their last trimester of pregnancy or first months of lactation. Sixteen women were diagnosed with PAO in Edinburgh over the past twenty years. They mainly presented with vertebral fractures (87.5%) and back pain (81.3%). On dual-energy X-ray absorptiometry (DEXA) scans, they had lower bone mineral density (BMD) at the spine than at the hip. Prior treatment with heparin (43.8%) was the most likely predisposing cause for their osteoporosis; when taken (in 31.3%), corticosteroids were usually inhaled. About a third of patients (31.3%) had a family history of osteoporosis. A systematic review of the literature on PAO revealed that vertebral fractures (89.2%) and back pain (90.2%) were the most common presentations of the disease. However, height loss of up to 10 cm (mean 4.8 cm) occurred in just over half of patients (54.9%). Calcium and vitamin D supplements (31.3%) and teriparatide (30.8%) were the most widely used treatments. Although a meta-analysis of BMD response to treatment was conducted, the results were inconclusive due to limited availability of data. A family history of osteoporosis was common among women with PAO (40.5%), and pathogenic variants for monogenic diseases associated with low BMD were also identified in 14.2% of cases. These included variants in COL1A1, COL1A2 and WNT1, which are known to cause osteogenesis imperfecta, as well as variants in LRP5, known to cause osteoporosis-pseudoglioma syndrome. An online survey of individuals with a self-reported diagnosis of PAO and controls of a similar age revealed that back pain, height loss and severe pain were highly predictive of the disease, with the area under a receiver operating curve (ROC) of these features combined being 0.988 (95% confidence interval 0.980 to 0.997). The study also revealed lower short- and long-term quality of life in PAO patients compared to controls, but this improved with time and bone-targeting osteoporosis medication. 49.8% of patients with PAO had a family history of osteoporosis, most commonly in the maternal (27.1%) and grandmaternal (22.7%) side of the family. Genetic analysis was conducted in a cohort of 69 individuals with PAO and 165 female controls. Targeted exome sequencing revealed that pathogenic variants in genes implicated in monogenic bone diseases were uncommon in our cohort. One patient had a pathogenic variant in COL1A1, two had pathogenic variants in WNT1, and one had a pathogenic variant in KDELR2, respectively (4/45, 8.9%). A polygenic risk score (PRS) analysis was also performed, and it determined that more single-nucleotide polymorphisms (SNPs) associated with lower BMD at the lumbar spine were present in women with PAO than controls. At the lumbar spine, the mean (± SD) beta-values of the SNPs were -2.37 ± 0.52 for cases compared to -2.13 ± 0.53 for controls (p=0.002). At the femoral neck, cases had fewer SNPs associated with low BMD, with mean beta-values of -1.45 ± 0.38 for cases compared to -1.80 ± 0.39 for controls (p<0.0001). This thesis advances knowledge on the risk factors for PAO, its mode of presentation and its short- and long-term effects on quality of life. It also demonstrates for the first time that predisposition to PAO is polygenic and caused by inheriting an excess of gene variants associated with low spine BMD. Nonetheless, pathogenic variants for monogenic bone diseases are present in a minority of cases.
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Orhadje, Elizabeth
- Advisors dc:contributor.advisor
-
- Ralston, Stuart
- Hauser, Barbara
Subjects
dc:subject × 8Rights
- Language dc:language.iso
- en
Identifiers
dc:identifier.*- Identifier URI
- https://doi.org/10.7488/era/7298